Bioisosteric replacement leading to biologically active [2.2]Paracyclophanes with altered binding profiles for aminergic g-protein-coupled receptors

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 7219-7228

  Skultety, Marika ^a   Hübner, Harald ^a   Löber, Stefan ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,5 DIMETHYLPHENYL) 4 [4 (2,5 DIMETHYLPHENYL) 4 HYDROXYPIPERIDIN 1 YL]BUTAN 1 ONE; 1 (2,5 DIMETHYLPHENYL) 4 [4 (2,5 DIMETHYLPHENYL)PIPERAZIN 1 YL]BUTAN 1 ONE; 1 (4 FUOROPHENYL) 4 [4 [[2.2]PARACYCLOPHAN 4 YL] 4 HYDROXYPIPERIDIN 1 YL]BUTAN 1 ONE; 1 [2,5 DIMETHYLPHENYL)] 4 [1,4 DIOXA 8 AZASPIRO[4.5]DEC 8 YL]BUTAN 1 ONE; 1 [2,5 DIMETHYLPHENYL] 4 [1,4 DIOXA 8 AZASPIRO[4.5]DEC 8 YL]BUTAN 1 ONE; 1 [4 (2,5 DIMETHYLPHENYL) 4 OXOBUTYL]PIPERIDIN 4 ONE; 1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL]PIPERIDIN 4 ONE; 1 [4 [[2.2]PARACYCLOPHAN 4 YL] 4 OXOBUTYL]PIPERIDIN 4 ONE; 1 [[2.2]PARACYCLOPHAN 4 YL] 4 [1,4 DIOXA 8 AZASPIRO[4.5]DEC 8 YL]BUTAN 1 ONE; 4 BROMO 1 (2,5 DIMETHYLPHENYL)BUTAN 1 ONE; 4 BROMO 1 [[2.2]PARACYCLOPHAN 4 YL]BUTAN 1 ONE; 4 [1,4 DIOXA 8 AZASPIRO[4.5]DEC 8 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE; 4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYRONITRILE; 4 [4 (2,5 DIMETHYLPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE; 4 [4 (2,5 DIMETHYLPHENYL)PIPERAZIN 1 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE; 4 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 1 (2,5 DIMETHYLPHENYL)BUTAN 1 ONE; 4 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 1 [[2.2]PARACYCLOPHAN 4 YL]BUTAN 1 ONE; 4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL] 1 (2,5 DIMETHYLPHENYL)BUTAN 1 ONE; 4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE; 4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL] 1 [[2.2]PARACYCLOPHAN 4 YL]BUTAN 1 ONE; 4 [4 [[2.2]PARACYCLOPHAN 4 YL] 4 HYDROXYPIPERIDIN 1 YL] 1 [[2.2]PARACYCLOPHAN 4 YL]BUTAN 1 ONE; 4 [4 [[2.2]PARACYCLOPHAN 4 YL]PIPERAZIN 1 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE; 4 [4 [[2.2]PARACYCLOPHAN 4 YL]PIPERAZIN 1 YL] 1 [[2.2]PARACYCLOPHAN 4 YL]BUTAN 1 ONE; 4 [4 [[2.2]PARACYCLOPHAN 4 YL]PIPERAZIN 1 YL]BUTYRONITRILE; G PROTEIN COUPLED RECEPTOR; PARACYCLOPHANE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ALPHA 1 ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; LIGAND; N-(4-(4-((2.2)PARACYCLOPHAN-4-YL)PIPERAZIN-1-YL)BUTYL)BENZO(B)THIOPHENYL-2-CARBOXAMIDE; SEROTONIN RECEPTOR; THIOPHENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SITE DIRECTED MUTAGENESIS; THIN LAYER CHROMATOGRAPHY; ANIMAL; BINDING COMPETITION; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; GENETICS; HAMSTER; HUMAN; IN VITRO STUDY; METABOLISM; MUTATION; RADIOASSAY; STRUCTURE ACTIVITY RELATION; SWINE; SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CRICETULUS; HUMANS; IN VITRO TECHNIQUES; LIGANDS; MODELS, MOLECULAR; MUTATION; PIPERAZINES; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THIOPHENES;

EID: 77957920179     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100899z     Document Type: Article

References (31)

1. Lopez-Munoz, F.; Alamo, C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice Brain Res. Bull. 2009, 79, 130-141
2. Scott, L. J. Iloperidone: in schizophrenia CNS Drugs 2009, 23, 867-880
3. Citrome, L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication Int. J. Clin. Pract. 2010, 64, 216-239
4. Janssen, P. A.; Niemegeers, C. J.; Schellekens, K. H.; Lenaerts, F. M.; Verbruggen, F. J.; van Nueten, J. M.; Marsboom, R. H.; Herin, V. V.; Schaper, W. K. The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug Arzneimittelforschung 1970, 20, 1689-1698
5. Harrison, T. S.; Perry, C. M. Aripiprazole. A review of its use in schizophrenia and schizoaffective disorder Drugs 2004, 64, 1715-1736
6. New, J. S. The discovery and development of buspirone: a new approach to the treatment of anxiety Med. Res. Rev. 1990, 10, 283-326
7. Deseure, K.; Breand, S.; Colpaert, F. C. Curative-like analgesia in a neuropathic pain model: Parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT1A receptor agonist Eur. J. Pharmacol. 2007, 568, 134-141
8. Kiss, B.; Horvath, A.; Nemethy, Z.; Schmidt, E.; Laszlovszky, I.; Bugovics, G; Fazekas, K.; Hornok, K.; Orosz, S.; Gyertyan, I.; Agai-Csongor, E.; Domany, G.; Tihanyi, K.; Adham, N.; Szombathelyi, Z. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J. Pharmacol. Exp. Ther. 2010, 333, 328-340
9. Brioni, J. D.; Moreland, R. B.; Cowart, M.; Hsieh, G. C.; Stewart, A. O.; Hedlund, P.; Donnelly-Roberts, D. L.; Nakane, M.; Lynch, J. J., III; Kolasa, T.; Polakowski, J. S.; Osinski, M. A.; Marsh, K.; Andersson, K.-E.; Sullivan, J. P. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6758-6763
10. Bettinetti, L.; Schlotter, K.; Hübner, H.; Gmeiner, P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists J. Med. Chem. 2002, 45, 4594-4597
11. Kortagere, S.; Gmeiner, P.; Weinstein, H.; Schetz, J. A. Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain Mol. Pharmacol. 2004, 66, 1491-1499
12. Ehrlich, K.; Götz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; Härterich, S.; Hübner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding J. Med. Chem. 2009, 52, 4923-4935
13. Schlotter, K.; Böckler, F.; Hübner, H.; Gmeiner, P. Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists J. Med. Chem. 2006, 49, 3628-3635
14. Ortner, B.; Waibel, R.; Gmeiner, P. Indoloparacyclophanes: synthesis and dopamine receptor binding of a novel arylbioisostere Angew. Chem, Int. Ed. 2001, 40, 1283-1285
15. Löber, S.; Ortner, B.; Bettinetti, L.; Hübner, H.; Gmeiner, P. Analogs of the dopamine D4 receptor ligand FAUC 113 with planar- and central-chirality Tetrahedron: Asymmetry 2002, 13, 2303
16. Hübner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype J. Med. Chem. 2000, 43, 756-762
17. Hayes, G.; Biden, T. J.; Selbie, L. A.; Shine, J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line Mol. Endocrinol. 1992, 6, 920-926
18. Sokoloff, P.; Andrieux, M.; Besanúon, R.; Pilon, C.; Martres, M.-P.; Giros, B.; Schwartz, J.-C. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor Eur. J. Pharmacol. 1992, 225, 331-337
19. Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H. H. M. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants J. Neurochem. 1995, 65, 1157-1165
20. Klabunde, T.; Evers, A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects ChemBioChem 2005, 6, 876-889
21. Mierau, J.; Schneider, F. J.; Ensinger, H. A.; Chio, C. L.; Lajiness, M. E.; Huff, R. M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors Eur. J. Pharmacol. 1995, 290, 29-36
22. Hübner, H.; Kraxner, J.; Gmeiner, P. Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments J. Med. Chem. 2000, 43, 4563-4569
23. Boeckler, F.; Ohnmacht, U.; Lehmann, T.; Utz, W.; Hübner, H.; Gmeiner, P. CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists J. Med. Chem. 2005, 48, 2493-2508
24. Cho, W.; Taylor, L. P.; Mansour, A.; Akil, H. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction J. Neurochem. 1995, 65, 2105-2115
25. Javitch, J. A.; Ballersteros, J. A.; Weinstein, H.; Chen, J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice Biochemistry 1998, 37, 998-1006
26. Tschammer, N.; Dörfler, M.; Hübner, H.; Gmeiner, P. Engineering a GPCR-ligand pair that simulates the activation of D2L by dopamine ACS Chem. Neurosci. 2010, 1, 25-35
27. Janssen, P. A. J. U.S. Patent US 2997472, 1961.
28. Schlotter, K.; Boeckler, F.; Hübner, H.; Gmeiner, P. Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles J. Med. Chem. 2005, 48, 3696-3699
29. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
30. Dörfler, M.; Tschammer, N.; Hamperl, K.; Hübner, H.; Gmeiner, P. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies J. Med. Chem. 2008, 51, 6829-6838
31. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108